Liminatus Clears Nasdaq Bid-Price Rule After Reverse Split

Liminatus Pharma said Nasdaq confirmed it had regained compliance with the exchange’s minimum bid-price rule. Nasdaq closed the matter after the company’s shares finished above $1 for 13 consecutive trading days.

Nasdaq notified Liminatus on Jan. 15, 2026, that its closing bid had been below $1 for 30 consecutive business days. That left the company out of compliance with the minimum bid-price requirement for the Nasdaq Global Market.

After an appeal and hearing, a Nasdaq panel transferred Liminatus to the Nasdaq Capital Market effective Aug. 4. It gave the company until Sept. 3 to meet that market’s bid-price requirement. Liminatus completed a 1-for-50 reverse stock split at the close of trading on Aug. 20.

In a Sept. 24 notice, Nasdaq said the closing bid was above $1 per share for 13 consecutive trading days, from Aug. 21 to Sept. 9. The company said Nasdaq’s determination restored its compliance.

Liminatus is a biotechnology company developing immuno-oncology and cell therapy candidates. Its programs include IBA101, an anti-CD47 antibody, and IBC101, a CAR-T candidate for B-cell malignancies.